A microRNA-125a variant, which affects its mature processing, increases the risk of radiation-induced pneumonitis in patients with non-small-cell lung cancer

HONG-YAN QUAN¹, TIAN YUAN¹ and JIAN-FENG HAO²

¹Oncology Department; ²Biological Center, Shaanxi Friendship Hospital, Xi'an, Shaanxi 710008, P.R. China

Received September 15, 2015; Accepted August 25, 2016

DOI: 10.3892/mmr.2018.9406

Abstract. The present study aimed to investigate the role of microRNA (miR)-125a in the development of pneumonitis in patients with non-small-cell lung cancer that received radiotherapy. In addition, the study aimed to determine how the miR-125a affects its target, transforming growth factor β (TGFβ). Bioinformatics tools were used to identify a potential miR-125a binding site in the 3′untranslated region of TGFβ, which was subsequently confirmed using a dual-luciferase reporter system. In addition, tissue samples were collected from patients with lung cancer and genotyped as CC (n=36), CT (n=28) or TT (n=6). The expression levels of miR-125a and TGFβ in these samples were determined, and CC genotype samples demonstrated upregulated miR-125a expression, and downregulated TGFβ protein and mRNA expression compared with samples carrying the minor allele, T. To further investigate the association between the rs12976445 polymorphism and the risk of pneumonitis in patients with lung cancer that received radiotherapy, 534 lung cancer patients diagnosed with pneumonitis and 489 lung cancer patients without pneumonitis were recruited. rs12976445 was shown to be significantly associated with the risk of pneumonitis. In conclusion, the rs12976445 polymorphism increased expression levels of TGFβ by decreasing the expression of miR-125a, and therefore may be associated with the development of pneumonitis in patients with lung cancer that receive radiotherapy.

Introduction

Lung cancer is the leading cause of cancer-associated mortality, with 1 million patients worldwide each year succumbing to this disease (1). The majority of lung cancer cases (≥80%) are non-small cell lung cancer (NSCLC), which consists of large cell carcinoma, adenocarcinoma and squamous cell carcinoma. However, ~30% of patients with NSCLC do not receive a specific classification (2,3). A standard treatment approach for patients with unresectable NSCLC is radiotherapy alone or combined with chemotherapy, as this may improve overall survival and control or reduce the lesion site, and prevent metastases (4). It has been reported that radiation-induced pneumonitis in patients with NSCLC is correlated with numerous factors (5). The most extensively investigated factors include dose-volume parameters to healthy lung tissue and selected cytokines (6); however, thus far none have been demonstrated to be accurate enough to control the radiation dose to prevent further damage. In addition, it is difficult to balance the requirement for high-dose radiation to achieve adequate tumor control with the need to limit the dose to healthy lung tissue in patients with larger tumors (7). A previous study demonstrated that inflammatory and fibrogenic cytokines are critical in the development of pneumonitis as a complication of radiotherapy (8). Inflammation may be regulated by transforming growth factor β (TGFβ), a pleiotropic cytokine that stimulates connective tissue collagen formation and reduces degradation, thus resulting in fibrosis (9). TGFβ has been revealed to be markedly associated with damage to the lung architecture (8). Previous studies have identified TGFβ as a marker of patients at risk of developing symptomatic pneumonitis (10,11).

In the majority of cells, differentiation, proliferation and other functions are controlled by the TGFβ1 gene. Numerous cellular processes in the developing embryo and the adult organism, including homeostasis, apoptosis, differentiation and growth are associated with the TGFβ1 signaling pathway (12). As an important modulator of the inflammatory response, TGFβ has been extensively investigated in the irradiation-induced development of tissue fibrosis (13). Plasma levels of TGFβ1 have been investigated as a predictor for lung injury induced by radiotherapy. Human and animal studies have indicated that TGFβ acts as primary regulator in the process of lung injury induced by radiation (14,15). Following administration of anti-TGFβ antibodies, TGFβ activation was reduced and the inflammatory response decreased several weeks after radiotherapy, further demonstrating that targeting the TGFβ signaling pathway may be a potential strategy to prevent lung injury induced by radiotherapy (16).

MicroRNAs (miRNAs) are endogenously encoded single-stranded RNAs ~22 nucleotides in length, which are
essential in various pathological conditions (17). miRNAs bind specifically to target messenger RNAs (mRNAs) and induce mRNA degradation or translational repression, resulting in posttranscriptional gene suppression (18). Various biological processes, including immunity, inflammation, cellular development, apoptosis, metabolism, differentiation and proliferation are regulated by miRNAs (17-19). However, a single nucleotide polymorphism (SNP; rs12976445) in pre-miRNA-125a may compromise the mature processing of the miRNA, reducing miR-125a production (20). Therefore, it has been hypothesized that rs12976445 may be associated with the risk of developing pneumonitis in patients with NSCLC treated with radiotherapy, by affecting the production of miR-125a, and consequently its target, TGFβ expression.

Materials and methods

Ethical considerations. The present study was conducted according to the Declaration of Helsinki guidelines and the study protocol was approved by the Human Ethics Committee of Shaanxi Friendship Hospital (Xi’an, China). Written informed consent was obtained from all participants prior to the study.

Patient eligibility and study design. The present study was performed on patients with NSCLC (n=1,023) who were admitted to the Oncology Department, Shaanxi Friendship Hospital. All patients received chest computed tomography (CT), pulmonary function tests, biochemical analysis, a complete blood count and a physical examination, and a complete medical history was taken (Table I). The patients were recorded and treated in accordance with the Radiation Therapy Oncology Group and the European Organization for the Research and Treatment of Cancer guidelines. All patients were followed up; assessments included chest CT, chest X-ray and a physical examination. Assessments were performed at three-month intervals for a period of two years following the completion of radiotherapy, and subsequently at six-month intervals. Patients were divided into two groups based on the presence or absence of pneumonitis (pneumonitis positive, n=534; pneumonitis negative, n=489). The criteria for enrollment in the present study included: i) A diagnosis of NSCLC; ii) no history of surgery and chemotherapy; iii) good heart, liver and kidney function; iv) no distant metastasis; v) no history of myocardial infarction, cerebral infarction or other critical illness in the previous six months; vi) a life expectancy of at least six months; and vii) a prescribed radiation dose of 50-70 Gy. Patients with any of the following were excluded: i) A history of surgery or chemotherapy for a thoracic tumor; ii) a history of severe pulmonary dysfunction or pulmonary fibrosis; iii) a history of total or partial pulmonary lobectomy; iv) poor general health; v) intolerance to radiation or incomplete radiotherapy; vi) a diagnosis of asthma, serious chronic bronchitis, emphysema or severe pulmonary infection; and vii) a diagnosis of another serious disease, including myocardial infarction and cerebral infarction within the previous six months. Lung tissue samples (70) were obtained from 1,023 NSCLC patients: [CC=36, 18 pneumonitis (+), 18, pneumonitis (-); CT=28, 14 pneumonitis (+), 14 pneumonitis (-); TT=6, 3 pneumonitis (+), 3 pneumonitis (-)] and genotyping for rs12976445 was conducted on blood samples obtained from all patients.

Genotyping. The QIAamp DNA Blood Mini kit (Qiagen, Inc., Valencia, CA, USA) was used to extract genomic DNA from blood (200 µl) samples, according to the manufacturer's protocol. Sanger sequencing using an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was performed to determine the genotype of rs12976445.

Cell culture and transfection. A549 human lung carcinoma cells were obtained from the American Type Culture Collection (Manassas, VA, USA), and were cultured in Dulbecco’s modified Eagle’s medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 100 mg/ml streptomycin, 100 U/ml penicillin and 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a 5% CO2 atmosphere. Lipofectamine™ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used to perform transient cell transfections of small RNAs or plasmids. miR-125a mimic/antagomir (5’-CTATGTATTGAAATGGCTTCAG-3’ and 5’-CGCGTC GCGCGTGTTTTAAACG-3’; Sangon Biotech Co., Ltd., China) or TGFβ small interfering (si)RNA (5’-CCCCAGA ACCAGGAGAAGA-3’ and 5’-UUCUUCUCUGGUUC UGGG-3’; Sangon Biotech Co., Ltd., China) were transfected at a final concentration of 100 nM. Briefly, the concentration of pcDNA3 was 16 µg/ml, the number of cells 2.0x10⁶/ml and the duration and temperature of the transfection was 6 h at 37°C. A scramble control oligo sequence with no known target in the human genome (5’-TGCACAATTTGATGC CGTTTATGAT-3’ and 5’-TTAAATGCAAGATGCTGA ACTGGAA-3’; Invitrogen; Thermo Fisher Scientific, Inc.) served as a control.

Plasmid construction, target prediction and luciferase assay. By scanning target gene prediction databases (www.targetscan.org), the putative target gene of the miR-125a was pooled from 3 databases. Experimental validation on miR-125a and TGFβ was performed. The full-length cDNA of the human TGFβ gene was amplified by polymerase chain reaction (PCR) and was subcloned into a pcDNA3 vector (Invitrogen; Thermo Fisher Scientific, Inc.) using the following cloning primer: Forward, 5’-ATGCCGCGCCCTTCCGGGCTGCGCTG CTCG-3’ and reverse, 5’-TCAGCTGCACTTGCAGAGCGCA CGG GTTTTTATGAT-3’ and 5’-TTAAATGCAAGATGCTGA ACTGGAA-3’; Invitrogen; Thermo Fisher Scientific, Inc.) served as a control.

Quan et al.: rs12976445 IS ASSOCIATED WITH PNEUMONITIS IN NSCLC
Table I. Demographic and clinicopathological features of the participants of the present study.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pneumonitis (+)</th>
<th>Pneumonitis (-)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>534</td>
<td>489</td>
</tr>
<tr>
<td>Sex (M:F)</td>
<td>534 (276:258)</td>
<td>489 (254:235)</td>
</tr>
<tr>
<td>Average age (years)</td>
<td>52.6±8.63</td>
<td>51.3±9.33</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>4.28</td>
<td>7.87</td>
</tr>
<tr>
<td>Current smokers (%)</td>
<td>12.14</td>
<td>2.86</td>
</tr>
<tr>
<td>Hyperlipidemia (%)</td>
<td>2.04</td>
<td>9.36</td>
</tr>
<tr>
<td>Diabetes mellitus (%)</td>
<td>2.34</td>
<td>1.27</td>
</tr>
<tr>
<td>Coronary heart disease (%)</td>
<td>7.68</td>
<td>6.12</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>20.25±1.41</td>
<td>21.03±0.97</td>
</tr>
</tbody>
</table>

M, male; F, female; Data expressed as mean ± standard deviation.

Figure 1. TGFβ3 was identified as a target gene of miR-125a, with the ‘seed sequence’ (390-397 bp) in the 3’ UTR of TGFβ3. TGFβ, transforming growth factor β; miR, microRNA; UTR, untranslated region; WT, wild type.

**Western blot analysis.** Cells were collected and lysed in radio immunoprecipitation assay buffer [1 mM phenylmethylsulfonyl fluoride, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, 1% NP-40, 10% glycerol, 1 mM diethiothreitol, 150 mM NaCl and 50 mM Tris-HCl (pH 8.0)]. Cell lysates were cleared of cell debris by centrifugation at 20,800 x g for 15 min at 4°C. The proteins were extracted using a BCA Protein Assay kit and the concentration was determined by ultraviolet absorption (21), using a BCA Protein Assay kit and the concentration was determined by ultraviolet absorption (21), prior to being separated by 12% SDS-polyacrylamide gel electrophoresis with 35 μg protein loaded on each lane and transferred onto a polyvinylidene difluoride membrane (GE Healthcare Life Sciences, Chalfont, UK). Membranes were blocked with 5% non-fat milk in Tris-buffered saline with 0.1% Tween-20 at room temperature for 2 h. The membranes were subsequently probed with primary antibodies against TGFβ (anti-mouse; 3711S; 1:10,000; Cell Signaling Technology, Inc., Danvers, MA, USA) and β-actin (anti-mouse; 4967S; 1:10,000; Cell Signaling Technology, Inc.). Following three washes with TBST, membranes were incubated with secondary antibody (Goat anti mouse-IgG-HRP; 1:10,000, Cell Signaling Technology, Inc.). Signals were developed using an Enhanced Chemiluminescence kit (Thermo Fisher Scientific, Inc.). Immuno reactive bands were quantified individually by estimating the number of pixels in ImageJ software version 1.4.1 (National Institutes of Health, Bethesda, MD, USA).

**Reverse transcription-quantitative PCR (RT-qPCR).** Total RNA was extracted from cells using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) in accordance with the manufacturer’s protocol, later tested by following 50 μl PCR reaction system: 37.5 μl ddH₂O, 10 mm dNTP 1 μl, 10×5 μl PCR buffer, 25 mm Mgcl 2 3 μl, upstream primer 1 μl, downstream primers 1 μl, template cDNA 1 μl (100°C water bath for 1 min, 0.5 μl Tag enzymes added over ice then 50 μl liquid paraffin added followed by centrifugation at 11,180 x g at 4°C for 1 min. PCR conditions were: 94°C 1 min, 58°C 30 sec, 72°C 90 sec, 40 cycles and then 72°C for 10 min, followed by storage at -20°C. RNAs were then reverse transcribed using the PrimerScript™ RT-PCR kit (Takara Biotechnology Co., Ltd., Dalian, China). qPCR was performed on the resultant cDNA using the SYBR® Green Master mix (Takara Biotechnology Co., Ltd.) to determine the expression of miR-125a. PCR-master mix (45 μl) containing 2 μl of enzyme-mix from the Qiagen OneStep RT-PCR kit (including the RT and the hot-start Taq polymerase), 1X RT-PCR buffer (included in kit) 400 μM of each dNTP, 20U of Riblock RNase Inhibitor (Fermentas; Thermo Fisher Scientific, Inc.) and 200 nM of each forward and reverse primer was added to 5 μl of previously treated sample RNA. The initial steps of the cycle program consisted of 30 min at 50°C to produce enough specific initial DNA and 15 min at 95°C for the activation of the Taq polymerase. Overall, 40 cycles of 15 sec at 95°C, 30 sec at 58°C and 1 min at 72°C were performed. Following a final elongation step at 72°C for 10 min, the amplification product was cooled at 8°C. The following primers were used (Sangon Biotech Co., Ltd.): Forward, 5'-CAGTGTCTGATA TGCGTCTGATG-3' and reverse, 5'-CTGATCTCGTCTG ATGCTAGCGTCG-3' for miR-125a; forward, 5'-CTGATCTGATG-3' and reverse, 5'-CTGATCTGATG-3' for TGFβ. U6 forward, 5'-ATGACAGCG ATATTCCCTGAGGCTGTAAGGTCTCCATA-3' and reverse, 5'-ATGCCAACCGCTTCAGCCCTGAGGGAATTT GCGTGTCA-3' small nuclear RNA served as an internal control for miRNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) forward, 5'-GCAGCCCTCAAGGCTG AGAAC-3' and reverse, 5'-TGGTGAACGGGCCAGTGA-3' for mRNA. Data was normalized to U6 and GAPDH using the 2⁻ΔΔCq method (22).

**Statistical analysis.** The relative expression of miRNA in each target was expressed (mean ± standard deviation/standard error of the mean), and the difference expression of miRNA between different groups was compared with non-paired test or single factor variance analysis. The Hardy-Weinberg equilibrium was tested using the Pearson’s Chi-square test (goodness-of-fit) for the SNP. Genotype distribution differences between cohorts were examined using the Pearson’s χ² test and logistic regression analysis. All statistical analyses were two-sided and were performed in SPSS software version 17.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference. The experiments were repeated three times.

**Results.**

**TGFβ is a target of miR-125a.** Based on reports that TGFβ was functionally involved in the development of pneumonitis in patients with lung cancer that received radiotherapy, and that miR-125a negatively regulates TGFβ, the present study aimed to investigate the molecular mechanism underlying...
pneumonitis, a primary adverse effect of radio therapy in the treatment of lung cancer, including the downstream mediators and signaling pathways of miR-125a. Online miRNA target prediction tools (http://www.targetscan.org) were used to search the target gene of miR-125a; these identified TGFβ as a candidate target gene in lung cancer cells with the ‘seed sequence’ (390-397 bp) in the 3'UTR of TGFβ (Fig. 1).

To verify TGFβ as a direct target gene of miR-125a, a dual-luciferase activity reporter assay was performed on miR-125a-overexpressing lung cancer cells transfected with wild-type TGFβ 3'UTR constructs or mutant TGFβ 3'UTR constructs. As presented in Fig. 2, compared with the scramble controls, cells transfected with wild-type TGFβ 3'UTR constructs exhibited reduced relative luciferase activity (P<0.05), whereas cells transfected with mutant TGFβ 3'UTR constructs demonstrated comparable luciferase activity (P>0.05), indicating that TGFβ was a direct target of miR-125a and that the binding site is located at 390-397 bp of the 3'UTR of TGFβ.

Effects of rs12976445 on miR-125a expression. Due to the negative regulatory association between miR-125a and TGFβ, the effect of the rs12976445 polymorphism on the interaction between miR-125a and TGFβ was investigated. C-509T is located 509 bp upstream of the exon1 codon of the gene. Tissue samples were collected from patients with lung cancer and genotyped as CC (n=36), CT (n=18) or TT (n=6). The miR-125a expression levels of the three genotypes were then analyzed. As presented in Fig. 3, the expression levels of miR-125a were significantly greater in the CC genotype group compared with the genotype groups carrying the minor allele, the CT and TT groups (P<0.05). These two groups exhibited comparable miR-125a expression levels, suggesting that the presence of the minor allele, T compromised the expression of miR-125a.

To investigate the association between the rs12976445 polymorphism and the risk of pneumonitis in patients with lung cancer that received radio therapy, 534 lung cancer patients with diagnosed pneumonitis and 489 lung cancer patients without pneumonitis were enrolled in the present study. The distributions of the rs12976445 polymorphism were in Hardy-Weinberg equilibrium among the case group and controls. As the expression levels of miR-125a were similar in the TT and CT groups, and significantly reduced compared with the CC group, a dominant model of the minor allele was indicated. Since the frequency of TT was relatively low in the population assessed, the CT and TT groups were combined. Significant differences were observed regarding genotype distribution of rs12976445 between patients with and without pneumonitis [odds ratio (OR)=1.43; 95% confidence interval (CI)=1.13-1.94; P=0.03], as presented in Table II. This is despite the fact that the polymorphism is not located in the binding site of miR-125a in the 3'UTR of TGFβ, and the effect of the polymorphism on the interaction between...
miR-125a and TGF\(\beta\) may therefore be attributed to an alteration in the secondary structure caused by the presence of the minor allele, or linkage disequilibrium with another variant that may directly cause the disruption between miR-125a and TGF\(\beta\). Alternatively, the polymorphism may compromise the transcription of TGF\(\beta\).

RT-qPCR and western blot analyses were performed to investigate the mRNA and protein expression levels of TGF\(\beta\) in each rs12976445 polymorphism genotype group. As presented in Fig. 4, the mRNA and protein expression levels of TGF\(\beta\) were reduced in the CC genotype group, compared with the minor-allele-carrying CT/TT genotype groups (P<0.05), which had decreased expression levels of miR-125a. These findings further support the hypothesis of the negative association between miR-125a and TGF\(\beta\).

To investigate the interaction between miR-125a and TGF\(\beta\), the mRNA and protein expression levels of TGF\(\beta\) in A549 cells transfected with TGF\(\beta\) siRNA, an miR-125a mimic, and anti-miR-125a were analyzed and compared with the scramble controls. TGF\(\beta\) protein expression levels were reduced in cells transfected with an miR-125a mimic or TGF\(\beta\) siRNA, compared with the scramble control (Fig. 5A). TGF\(\beta\) protein expression levels were greater in cells transfected with anti-miR-125a, compared with the scramble control (Fig. 5B). A similar pattern was observed in TGF\(\beta\) mRNA expression levels (P<0.05; Fig. 5C and D). The above findings further validate the negative association between miR-125a and its target TGF\(\beta\).

**Discussion**

A common complication of lung radiotherapy, radiation-induced lung injury, including radiation fibrosis and pneumonitis, is associated with a poor prognosis. Radiotherapy-induced pneumonitis may be predicted by pulmonary function parameters in the clinic (23). The infiltration of inflammatory cells into alveolar spaces and the pulmonary interstitium is a characteristic of pneumonitis at the cellular level. In the present study, bioinformatics tools were used to identify potential binding sites of miR-125a in the 3'UTR of TGF\(\beta\), and this was subsequently confirmed using a dual-luciferase reporter system. In addition, tissue samples were collected from patients with lung cancer and genotyped as CC (n=36), CT (n=28) or TT (n=6). The expression levels of miR-125a and TGF\(\beta\) were determined in these samples, which exhibited upregulated miR-125a and downregulated TGF\(\beta\) protein and mRNA expression levels in cells genotyped as CC compared with cells carrying the minor allele, T.

It has previously been demonstrated that cytokines are involved in the development of pneumonitis (24). TGF\(\beta\) is involved in the pathogenesis of radiation-induced pneumonitis; therefore, the outcomes of patients with radiation-induced pneumonitis may be predicted by TGF\(\beta\) expression. As a ubiquitous profibrotic and immunomodulatory cytokine, TGF\(\beta\) is essential in tissue responses to irradiation. It has been observed that rising plasma levels of TGF\(\beta\) during thoracic radiotherapy is associated with the subsequent occurrence of radiation-induced pneumonitis (25-27). As a result, TGF\(\beta\) has been adopted as a sensitive plasma marker of radiation-induced pneumonitis following thoracic irradiation. A previous animal study demonstrated that anti-TGF\(\beta\) antibodies decreased the levels of TGF\(\beta\) during thoracic irradiation, resulting in attenuation of radiation-induced pneumonitis (28). In the present study, miR-125a was identified as a regulator of TGF\(\beta\) in A549 cells using in silico analysis and a dual-luciferase reporter system.

Previous studies have demonstrated that the C-509T SNP is associated with TGF\(\beta\) gene promoter activity enhancement, and the T allele of C-509T is associated with increased serum levels of TGF\(\beta\). The serum level of TGF\(\beta\) in the CC genotype is decreased compared with the CT or TT genotypes (29). In addition, a previous study revealed that greater circulating TGF\(\beta\) levels during radiation therapy are correlated with poor prognosis of locally advanced NSCLC (30). Therefore, compared with those with TGF\(\beta\) C-509T CT or TT genotypes, patients with CC genotype may have improved survival due to reduced circulating TGF\(\beta\) levels during radiotherapy. Furthermore, various studies have implicated TGF\(\beta\) in radiation-induced lung injury; in particular, a persistently elevated or rising level of TGF\(\beta\) during the course of thoracic radiation therapy has been associated with symptomatic radiation pneumonitis (14,27). Since miR-125a was identified as a regulator of TGF\(\beta\) and rs12976445 interferes with the mature processing of this miRNA, reducing the mRNA expression levels, the present study examined the effect of rs12976445 on the expression levels of miR-125a and TGF\(\beta\). The expression levels of miR-125a were markedly greater in the CC genotype group compared with those carrying the minor allele, the CT and TT groups, which exhibited comparable miR-125a expression levels, indicating that the T allele is dominant.

The MIR125A gene, which encodes miR-125a, is situated in a gene cluster on chromosome 19q13.41. miR-125a has been reported to be involved in the pathogenesis of human diseases, including verrucous carcinoma (31), ovarian cancer (32), gastric cancer (33), breast cancer (34) and systemic lupus erythematosus (35). It has previously been demonstrated that an SNP (rs12976445) in the precursor of miR-125a, located in the stem loop of the molecule, may undermine the mature processing of the miRNA, leading to a decrease in the production of miR-125a (21). In the present study, 534 lung cancer patients with diagnosed pneumonitis and 489 lung cancer patients without pneumonitis were recruited, and significant differences were noted regarding genotype distribution of
rs12976445 between those with and without pneumonitis (OR=1.43; 95% CI=1.13-1.94; P=0.03).

In conclusion, the results of the present study demonstrated that patients with radiation-induced pneumonitis have decreased expression levels of miR-125a in lung tissue. Presence of the minor allele of the rs12976445 polymorphism increased expression levels of TGFβ by decreasing the expression levels of miR-125a, and therefore may be associated with the development of pneumonitis in patients with lung cancer receiving radio therapy. These results suggested that rs12976445 may be a potential biomarker to predict the risk of pneumonitis following radio therapy.

Acknowledgements
Not applicable.

Funding
No funding was received.
TGF-β1 and radiation

Glycine

Gene-modified mesenchymal stem cells protect

Changes in

Genetic control of the

Does transforming

Genotypes and haplotypes

Competing interests

prior to the study.

of Helsinki guidelines and the study protocol was approved by

approved the final manuscript.

Authors' contributions

H-YQ planned the study, collected and interpreted the data, assembled the literature and wrote the manuscript. TY collected and interpreted the data, and wrote the manuscript. J-FH interpreted the data, assembled the literature and approved the final manuscript.

Ethics approval and consent to participate

The present study was conducted according to the Declaration of Helsinki guidelines and the study protocol was approved by the Human Ethics Committee of Shaanxi Friendship Hospital.

Patient consent for publication

Written informed consent was obtained from all participants prior to the study.

Competing interests

The authors declare that they have no competing interests.

References


